Innovation Pharmaceuticals Inc.
IPIX evidence brief
What we can confirm
- BioSniper Score:
- 4.9 / 10
- Market Cap:
- $156K
- Lead Asset:
- brilacidin (Phase 2)
What it means
What to watch
Prepared research question
What matters most for IPIX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Tracking 2 pipeline candidates · 113 clinical trials · 1 catalyst for Innovation Pharmaceuticals Inc..
Run Innovation Pharmaceuticals Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Innovation Pharmaceuticals Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
2 candidates
1 upcoming, next in ~80d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Frequently asked questions
What is Innovation Pharmaceuticals Inc.'s lead drug candidate?
Innovation Pharmaceuticals Inc.'s most advanced tracked candidate is brilacidin (Phase 2) for Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
What is Innovation Pharmaceuticals Inc.'s next catalyst?
Innovation Pharmaceuticals Inc.'s next tracked catalyst is a Phase3_Start event — "Phase3_Start: An Open Label Safety Study of a Single Administration of F14 in Patients Undergoing Unilateral Total Knee Replacement" — expected January 1, 2027.
Who is the CEO of Innovation Pharmaceuticals Inc.?
Mr. Leo Ehrlich CPA is the chief executive officer of Innovation Pharmaceuticals Inc. (IPIX).
Where is Innovation Pharmaceuticals Inc. headquartered?
Innovation Pharmaceuticals Inc. (IPIX) is headquartered in Wakefield, MA, United States.
What therapeutic areas does Innovation Pharmaceuticals Inc. focus on?
Innovation Pharmaceuticals Inc. develops therapies across Oncology, Rare Disease, Neurology, Immunology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain, Dermatology, Nephrology, Musculoskeletal, Gastroenterology, Reproductive, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.